BridgeBio to present infigratinib data at ESPE meeting in September
BridgeBio Pharma (NASDAQ: BBIO) announced it will present data on oral infigratinib in achondroplasia at the Annual European Society for ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)